Standard Medical Care

ApprovedSmall molecule

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Standard Medical Care is one of 195 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.

Indications

Total Trials

Active Trials

194

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

RadiculopathyActive, not recruiting

Iron Deficiency AnemiaActive, not recruiting

Back PainActive, not recruiting

Prostate CancerActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Systemic Lupus ErythematosusApproved

Active, not recruiting

RadiculopathyApproved

Active, not recruiting

Iron Deficiency AnemiaPhase 3

Active, not recruiting

Back PainPhase 3

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Standard Medical Care

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Approved

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Viagra

VViatris Specialty LLC

Preclinical

1 8

Duragesic

CCephalon

Preclinical

1 9

Prednisone/prednisolone

Roche

Preclinical

3 10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Not yet recruiting

Prostate Cancer

NCT07310433

Q2 2033

N/ARecruiting

PCSK9 Inhibitor

NCT06863545

Clinical

Trials by Indication[1]

Iron deficiency anemia2 trials

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

Completed·AAmerican Regent, Inc.·Phase 3·NCT00548860·2,018 enrolled

Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia

Completed·AAmerican Regent, Inc.·Phase 3·NCT00704353·735 enrolled

Terminated·MMontefiore Medical Center·Phase 4·NCT01267825·1 enrolled

3 more indications

Prostate Cancer1 trial

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

Not yet recruiting·YYung NA·Phase 2·NCT07310433·60 enrolled

Chronic Kidney Disease1 trial

Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

Completed·AAmerican Regent, Inc.·Phase 3·NCT00548691·513 enrolled

Back pain1 trial

Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain

Completed·UUniversity of Minnesota·Phase 3·NCT03581123·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Standard Medical Care. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard Medical Care compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard Medical Care. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Standard Medical Care

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Q2 2033

Trials by Indication[1]

Iron deficiency anemia2 trials

Systemic Lupus Erythematosus1 trial

PCSK9 Inhibitor1 trial

Acute Lymphoblastic Leukemia1 trial

Radiculopathy1 trial

Prostate Cancer1 trial

Chronic Kidney Disease1 trial

Back pain1 trial

References

Drug Info

Quick Facts

Related News